Detalles de la búsqueda
1.
Improved nationwide survival of sarcoma patients with a network of reference centers.
Ann Oncol
; 35(4): 351-363, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38246351
2.
Clinical utility of circulating tumor DNA sequencing with a large panel: a National Center for Precision Medicine (PRISM) study.
Ann Oncol
; 34(4): 389-396, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36709039
3.
Impact of acetaminophen on the efficacy of immunotherapy in cancer patients.
Ann Oncol
; 33(9): 909-915, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35654248
4.
ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group.
Ann Oncol
; 33(8): 750-768, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35809752
5.
Circulating L-arginine predicts the survival of cancer patients treated with immune checkpoint inhibitors.
Ann Oncol
; 33(10): 1041-1051, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35850444
6.
Treatment with a retinoic acid-inducible gene I (RIG-I) agonist as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: results from two phase 1 studies.
Cancer Immunol Immunother
; 71(12): 2985-2998, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-35596791
7.
Health-related quality of life with pembrolizumab monotherapy in patients with previously treated advanced microsatellite instability high/mismatch repair deficient endometrial cancer in the KEYNOTE-158 study.
Gynecol Oncol
; 166(2): 245-253, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35835611
8.
Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), and Spanish Group for Research on Sarcomas (GEIS)â.
Ann Oncol
; 32(4): 533-541, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33482247
9.
Plasma proteomics identifies leukemia inhibitory factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance.
Ann Oncol
; 32(11): 1381-1390, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34416362
10.
A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trial.
Ann Oncol
; 32(8): 1034-1044, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33932507
11.
Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages.
Ann Oncol
; 30(8): 1381-1392, 2019 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31114846
12.
Surgery in reference centers improves survival of sarcoma patients: a nationwide study.
Ann Oncol
; 30(7): 1143-1153, 2019 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31081028
13.
Localized high grade endometrial stromal sarcoma and localized undifferentiated uterine sarcoma: a retrospective series of the French Sarcoma Group.
Int J Gynecol Cancer
; 29(4): 691-698, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30772825
14.
WGS/WES-RNAseq compared to targeted NGS in oncology: is there something to unlock?
Ann Oncol
; 34(12): 1090-1093, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37816462
15.
The Genomic Grade Index predicts postoperative clinical outcome in patients with soft-tissue sarcoma.
Ann Oncol
; 29(2): 459-465, 2018 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29069276
16.
CHK1 inhibition in soft-tissue sarcomas: biological and clinical implications.
Ann Oncol
; 29(4): 1023-1029, 2018 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29409053
17.
Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors.
Ann Oncol
; 29(5): 1304-1311, 2018 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29788155
18.
Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 'CREATE'.
Ann Oncol
; 29(3): 758-765, 2018 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29216400
19.
Mature tertiary lymphoid structure is a specific biomarker of cancer immunotherapy and does not predict outcome to chemotherapy in non-small-cell lung cancer.
Ann Oncol
; 33(10): 1084-1085, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35764273
20.
Improved survival using specialized multidisciplinary board in sarcoma patients.
Ann Oncol
; 28(11): 2852-2859, 2017 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29117335